Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
Skin Trust Club partners with Media.Monks to accelerate global expansion of hyper-personalised skincare brand launch
Open Orphan Executive Chairman Cathal Friel joins Yahoo Finance Live to discuss how his company is testing vaccines through intentional infection.
The planet is in trouble. Humanity’s health is in trouble. One of the main ways the environment is telling us this is in the information we can glean from wastewater
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.
Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry (“MS”) instruments and analytical solutions, is pleased to announce its unaudited interim results for the six months
Further to the Heads-of-Terms announced on 9 August 2021, Microsaic has confirmed its signing of an agreement (‘the Agreement’) with Jiangsu Henzhihe Technologies Co. Ltd.
Microsaic sign manufacturing, supply, and service agreement to support China operations Production assembly to commence this year and on track for China medical device licence in 2022
Kanabo Group Plc (LSE:KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, announces Kanabo’s CBD products
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
